Sales and Marketing

Showing 15 posts of 11528 posts found.

The need for flexible appraisal of rare disease medicines

March 15, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amryt Pharma, feature, pharma, rare disease, rare diseases

Recent data has shown that England is, on average, slower than Germany, France, Spain and Italy in making orphan medicinal …

Roche appoints new research and early development head

March 15, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Roche, appointment

Dr John C Reed, Roche’s Head of Pharma Research and Early Development (pRED), is set to leave the company due …

Fat-fighting pharma business files for bankruptcy

March 15, 2018 Sales and Marketing Contrave, biotech, drugs, orexigen, pharma, pharmaceutical

Orexigen Therapeutics, a biotech that was one of a wave of companies bringing through weight-loss pills, has announced that it …

Takeda’s CFO departs forcing company to act

March 14, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Takeda, biotech, drugs, pharma, pharmaceutical

Takeda has announced that its Chief Financial Officer, James Kehoe, has decided to move on from the company to take …

Teva denies wrongdoing in Cephalon pay-to-delay deal hearing

March 14, 2018 Research and Development, Sales and Marketing Cephalon, Pay to delay, Provogil, Teva, pay-to-delay, pharma

Teva has denied allegations from the European Commission (EC) that it engaged in illegal anti-competitive pay-to-delay tactics to maintain its …

US “right to try” experimental drug bill defeated in House vote

March 14, 2018 Research and Development, Sales and Marketing FDA, House of representatives, Right to try, US, pharma

The divisive and much-talked-about “right to try” legislation designed to provide access for terminally ill Americans to experimental and unproven …

Pfizer begins sell-off, shedding CNS drug to Biogen for $590m

March 13, 2018 Manufacturing and Production, Sales and Marketing Biogen, CNS, Pfizer, biotech, drugs, pharma, pharmaceutical

Pfizer’s decision to back out of the neuroscience space was a strategic move that send shudders through the entire industry, …

Drug safety: EudraVigilance and an evolving system

March 12, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing drug safety, pharma, pharmacovigilance

The importance of drug safety is back in the news due to sodium valproate and Ben Hargreaves examines how the …

AstraZeneca’s Brilinta proves safety in heart attack patients at Phase 3

March 12, 2018 Research and Development, Sales and Marketing AstraZeneca, Brilinta, heart attack

AstraZeneca has revealed new Phase 3 data on its direct-acting P2Y12 receptor antagonist Brilinta (ticagrelor) at the American College of …

Impax agrees to $35 million settlement over anticompetitive practices with Valeant generic

March 12, 2018 Sales and Marketing Impax, Medicis, Solodyn, Valeant, generic, pharma

Impax Pharmaceuticals has acquiesced to paying a $35 million settlement in order to resolve part of an antitrust lawsuit it …

Martin Shkreli sentenced to seven years in jail for securities fraud

March 12, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Martin Shkreli, pharma

Three years after he became “the most hated man in America” overnight for jacking up the price of life-saving HIV-related …

Sanofi and Regeneron reveal strong data and a price drop for Praluent

March 12, 2018 Research and Development, Sales and Marketing Regeneron, Sanofi, pharma, praluent

Sanofi and Regeneron have revealed strong new data for its PCSK9 inhibitor Praluent showing the first-ever reduction in deaths within …

Hikma’s Advair generic delayed in the US

March 12, 2018 Sales and Marketing Advair, FDA, GSK, GlaxoSmithKline, pharma

Hikma Pharmaceuticals has been knocked back with the news that the FDA has delayed approval of its generic lung treatment …

GSK loses £37m appeal over pay-to-delay tactics to block Seroxat competition

March 9, 2018 Medical Communications, Sales and Marketing GSK, Pay to delay, Seroxat, antidepressant, pay-to-delay, pharma

GlaxoSmithKline has suffered a sizeable blow after losing an appeal disputing that it had engaged in anti-competitive pay-to-delay tactics to …
The Gateway to Local Adoption Series

Latest content